On March 14, the FDA approved the nation’s first medication to treat noncirrhotic non-alcoholic steatohepatitis with fibrosis, or fatty liver scarring.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
FDA approves 1st MASH therapy
